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Fatty acid synthase (FASN) is the enzyme that synthesizes fatty acids de novo in human cells. Although
FASN is generally expressed at low levels in most normal tissues, its expression is highly upregulated in
many cancers. Consistent with this notion, inhibition of FASN activity has demonstrated potential to halt
proliferation and induce cell death in vitro and to block tumor growth in vivo. Consequently, FASN is widely
recognized as a valuable therapeutic target. In this report, we describe a variety of 1,4-quinones and 9,10anthraquinones, including several natural compounds and some newly synthesized compounds, that potently
inhibit the thioesterase (TE) domain of FASN. Inhibition of recombinant TE activity, inhibition of cellular
FASN, and cytotoxicity in human prostate cancer cell lines and normal ﬁbroblasts, is shown for the most
potent inhibitors. Collectively, the data illustrate the novel inhibitory capacity of the 1,4-quinone and 9,10anthraquinone pharmacophores against FASN.
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Fatty acid synthase (FASN) is the enzyme that synthesizes
fatty acids in mammalian cells. FASN is a multifunctional
protein comprised of seven functional domains. Over expression of FASN is a common characteristic of most tumors, and
FASN expression levels correlate with disease progression.1)
Accordingly, FASN activity is essential for the survival of
cancer cells and tumor growth. Because this enzyme is absent
in most normal adult tissues, there may be an opportunity to
achieve a high therapeutic index with FASN-directed therapeutics that may be devoid of side effects typically associated
with conventional anti-cancer agents. The FDA-approved drug
Orlistat inhibits the thioesterase (TE) domain of FASN and
can kill cancer cells in cell culture and xenograft models.2)
However, Orlistat suffers from poor solubility and systemic
bioavailability, and thus is not suitable as a cancer therapeutic
in the current formulation.
In an effort to identify novel discovery leads, a library of
8800 compound library (Nanosyn, Inc., U.S.A.) was screened
using the recombinant FASN-TE domain in an assay containing 10 µM of each compound and 4-methylumbelliferyl
heptanoate as the substrate.3,4) Among the compounds that
inhibited FASN-TE was 2-bromo-3-methyl-1,4-benzoquinone
(NS-4390, 1a) (Fig. 1). Interestingly, the 1,4-dione moiety is
found in a wide range of bioactive molecules in the animal,
fungal and plant kingdoms—the vitamin K family being a
notable example.5,6) These compounds can modulate cellular
redox pathways and exhibit a broad range of biological activities.7) Salient to this manuscript are recent investigations into
the cytotoxic and anti-proliferative properties of compounds
containing 1,4-benzoquinone (common name) moiety.8–13) To
the best of our knowledge, inhibition of the TE domain of
FASN has not been postulated as a mechanism for the ability
of this class of compounds to inhibit tumor growth.
The authors declare no conflict of interest.
†
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An analysis of naturally occurring, commercially available,
and new synthetic 1,4-benzoquinones, 1,4-naphthoquinones,
9,10-anthraquinones (Fig. 1, Chart 1) was performed to develop structure–activity relationship (SAR) information for
FASN-TE at an initial concentration of 10 µM. Included are the
naturally occurring compounds menadione (1c), plumbagin
(1d), lawsone (1e), juglone (1g), and naphthazarin (1i). The
1,4-naphthoquinones (1a–i) and 1,4-benzoquinones (2a–g)
(Table 1) display potent inhibition of FASN-TE, except for
compound 1e. In contrast, the more complex naturally occurring compounds (3–7) inhibit with less potency (Table 1). The
1,4-quinones with known anti-cancer activity like mitomycin
C, doxorubicin, geldanamycin, streptonigrin and mitoxantone
did not inhibit; lapachol and β-lapachone exhibited weak inhibition potency (data not shown). All of the 1,4-benzoquinones
(2a–c, 2e–g) with the exception of 2d show complete inhibition (Table 1) of FASN-TE at 10 µM, but because of their high
level of chemical reactivity were not assessed further with TE
or in cellular assays.
The IC50 values against recombinant TE were determined
for compounds 1a–i, 2e–g, and 3. The 1,4-naphthylquinones
(1a–i) show a much wider SAR proﬁle with the IC50 values
ranging from 0.1 µM to greater than 100 µM. As expected,
compounds 1b, 1f, and 1g had the lowest IC50 values of
0.9 µM, 0.3 µM, and 0.1 µM, respectively, and compound 1e had
the highest IC50 value of over 100 µM. Based on this dataset,
we reasoned that the structure–activity is driven principally
by substituent effects of moieties directly attached to the
quinone ring. Overall activating groups (Electron Donating
Groups, EDGs) diminish inhibition, while deactivating groups
(Electron Withdrawing Groups, EWGs) have nominal to a
positive effect on inhibition. Compound 1e containing a strong
EDG consistent with the SAR has low inhibition capacity;
likewise compound 4 with three weak EDGs is a nominal
inhibitor. The natural products 6 and 7 that contain strong
EDGs (methoxy and hydroxy) also show diminished ability to
inhibit TE. Importantly, the best compounds are comparable

2014 The Pharmaceutical Society of Japan
*©
To whom correspondence should be addressed. e-mail: tlowther@wakehealth.edu;
jschmitt@wakehealth.edu

934

Fig. 1.
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1,4- and 9,10-Diones Tested against Recombinant FASN-TE and FASN

Chart 1

in potency to Orlistat and its congener Ebelactone B, with IC50
values of 0.3 and 0.8 µM, respectively.
In an effort to test substituent effect hypotheses and to
reduce overall chemical reactivity, several analogs were synthesized: one compound with a strong EDG (1h) resulting
from the treatment of juglone with morpholine and some with
weak to very weak electron donating groups (EDGs; 2e–g).
As shown in Chart 1, these compounds were synthesized by
reaction of the quinone precursor with a sulfur or nitrogen nucleophile leading to the substituted 1,4-dihydroxy compound
(the reduced form of the quinone). Oxidation of the thiol intermediates was accomplished in high yield by dissolving the

thiol substrates in methylene chloride and using an aqueous
solution of sodium periodate and benzyltrimethylammonium
bromide as a phase transfer catalyst13) to afford the desired
product (2e–g). In contrast, the morpholino containing intermediate auto-oxidized to provide the desired compound (1h).
Supporting our hypothesis, the thio compounds (2e–g) are
potent inhibitors; while the morpholino compound (1h) was
a nominal inhibitor. The improved inhibition of the former
compounds is most likely due to their lack of aromatic rings
around the 1,4-benzoquinone core structure, as the naphthoquinone 1h or the anthraquinone 5 do, and the missing
electron cloud of the phenyl rings decreases the electron do-
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Table 1.

Effect of 1,4- and 9,10-Diones on FASN-TE, Fatty Acid Synthesis and Cell Killing

Cmpd

1a
1b
1c
1d
1e
1f
1g
1h
1i
2a
2b
2c
2d
2e
2f
2g
3
4
5
6
7

rTEa)
% Inhibition
at 10 µM

rTE
IC50 (µM)

78
100
54
59
10
100
100
26
98
100
100
100
66
99
96
100
4
39
35
30
31

12.5
0.9
21.9
10.9
>100
0.3
0.1
26.4
3.5
—b)
—b)
—b)
—b)
6.4
6.2
0.2
52.4
—b)
—b)
—b)
—b)

Inhibition of
FA synthesis
IC50 (µM)

Cell killing EC50 (µM)

PC-3

FS4

PC-3

DU145

10
2.8
—b)
2.4
—b)
11.5
6.8
—
2.6
—b)
—b)
—b)
—b)
>25 µM
>25 µM
>25 µM
>25 µM
—b)
—b)
—b)
—b)

9.4
10.6
16.7
2.3
>50
21
6.3
—b)
2.4
—b)
—b)
—b)
—b)
—b)
—b)
—b)
31.1
—b)
—b)
—b)
—b)

11.8
12.8
48.4
4.1
>100
23.3
5.8
—b)
2.7
—b)
—b)
—b)
—b)
—b)
—b)
—b)
8.3
—b)
—b)
—b)
—b)

19.2
6.8
—b)
5.3
—b)
35.4
10.6
—b)
4.8
—b)
—b)
—b)
—b)
—b)
—b)
—b)
—b)
—b)
—b)
—b)
—b)

a) Recombinant TE domain of human FASN. b) Not determined.

nating capability of the 2-alkyl-substituted 1,4-benzoquinone
derivatives. We surmise that Michael addition is one plausible
mechanism for enzyme inhibition, though analogs with fully
substituted quinone rings (1a, 5, 6, 7) still retain the ability to
inhibit. Further work will be required to develop a mechanistic basis for the observed SAR; for example, afﬁnity measurements (Ki) and determination of reversibility of inhibition will
be critical in uncovering the physicochemical determinants of
the observed inhibition data.
Inhibition of cellular FASN activity was performed for
selected compounds in two prostate cancer cell lines (PC3
and DU145) and in normal ﬁbroblast (FS4) using an assay
that measures the incorporation of the 14C-acetate precursor
into lipids.14) Not surprisingly, likely owing to low solubility
in solution and cellular availability, there is little correlation
between the ability of a compound to inhibit recombinant TE
and inhibition of cellular FASN activity (Pearson’s R=0.1).
Interestingly, the compounds that best inhibited 14C-acetate incorporation are in the simple 1,4-naphthoquinone family (1a,
1b, 1d, 1f, 1g, 1i). The most potent inhibitors of recombinant
TE that showed no inhibition of endogenous enzyme are the
2-thio-substituted 1,4-benzoquinones (2e–g). A high level of
nonspeciﬁc chemical reactivity and/or a myriad other factors
may be contributing to the observed contrast in SAR between
these assays.
There is also a correlation between the ability of a quinone
analog to inhibit cellular FASN and the potency (EC50) at killing tumor cells. The inhibition of 14C-acetate uptake and EC50
for inhibition of PC3 cell growth is correlated with a Pearson’s
r=0.85. Prostate cancer cells expressing the highest level of
FASN (DU145) used in this study show an even higher correlation, r=0.92. Despite this strong relationship, only a few

of the compounds demonstrated a marginal therapeutic index
which was calculated as the cell killing ratio of cancer and
FS4 ﬁbroblasts EC50 values (data not shown). Based on the
8 µM EC50 value of Orlistat for PC-3 cells and negligible cytotoxicity to ﬁbroblasts and normal epithelial cells; the compounds studied herein clearly need signiﬁcant optimization to
move toward therapeutic use.2)
In summary, we have demonstrated that 1,4-benzoquinones
and 1,4-naphthoquinones, as well as a number of natural
products containing the 1,4-benzoquinone and the 9,10anthraquinone moieties, inhibit the TE domain of FASN as
well as cellular FASN activity. These compounds are not
based on Orlistat structure, thus are expected to have different pharmacological properties than Orlistat. Nonetheless, the
ability of these compounds to inhibit human pancreatic lipase
will need to be performed in the future. We surmise that the
bioactivity of these compounds may in some cases contribute
to the widely observed anti-cancer properties of 1,4-quinones.7–12) Additionally, the SAR shown herein is a startingpoint for the rational design of therapeutics that target the TE
domain of FASN that are distinct from Orlistat.

Experimental

General All reagents and solvents were used as purchased
without further puriﬁcation. 1H-NMR spectra were recorded in
the indicated solvent on a Bruker 300 MHz with tetramethylsilane (TMS) as internal standard (chemical shift in δ ppm).
Mass [ES-MS (70 eV)] spectra were recorded on Agilent 1100
LC/MSD spectrophotometer. Analytical TLC was performed
on Silica Gel GHLF250 plates (Analtech) with visualization by
UV (254 nm) chamber with protective ﬁlters. All compounds
were puriﬁed by precipitation or by column chromatography
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performed on silica gel (230–400 mesh, grade 60, Fisher).
Synthesis of 8-Hydroxy-2-morpholinonaphthalene-1,4dione (1h) To a solution of juglone (30 mg, 0.172 mmol) in
ethanol (1.4 mL) was added morpholine (17 µL, 0.172 mmol)
at room temperature. A dark precipitate was observed. The
sample was stirred at room temperature for 20 h, and then it
was ﬁltered (paper) and rinsed with cold ethanol (ca. 2 mL)
and dried to give 34 mg (76% isolated yield) of 8-hydroxy2-morpholinonaphthalene-1,4-dione as a purple-brown solid.
1
H-NMR (DMSO-d6) δ: 7.655 (1H, t, J=0.028, 0.025 Hz),
7.408 (1H, d, J=0.024 Hz), 7.199 (1H, d, J=0.028 Hz), 5.993
(1H, s), 3.700–3.696 (4H, br s), 3.450–3.299 (4H, br s), 2.049
(1H, s). LCMS m/z: 260 [{M+1}+].
General Procedure for the Synthesis of 2-Alkylthio-1,4benzoquinones (2e–g) To a solution of 1.0 eq (2.11 mmol)
of 1,4-benzoquinone in ethanol (9.2 mL) was added 1.0 eq
(2.11 mmol) of thio-derivative at room temperature. The
sample was stirred at room temperature for 1 h and monitored
by thin layer chromatography until it was complete. Ethanol
was removed by reduced pressure to obtain a solid (usually
brown to orange in color) that was collected by ﬁltration or
puriﬁed by flash column chromatography with a hexane–ethyl
acetate gradient. The resulting 2-alkylthiohydroxyquinone
was dissolved in methylene chloride, placed in a separatory
funnel and treated with an aqueous 0.467 M solution of 1.0 eq
(2.11 mmol) of sodium periodate and a 0.022 eq (0.046 mmol)
of benzyltrimethylammonium bromide (phase transfer reagent) and was shaken for 20 min in a Glas-Col Bench Top
Shaker at room temperature. Reaction completion was identiﬁed by TLC. Upon completion, the heterogeneous mixture
was washed with water (2×10 mL and brine (10 mL). The
aqueous layers were back-extracted with methylene chloride
(10 mL). The organic layers were combined, dried (Na2SO4),
ﬁltered (paper) and concentrated to dryness in vacuo to afford the desired compounds as a solid. The resulting solid was
puriﬁed by column chromatography, using hexanes and ethyl
acetate gradient as mobile phase or by precipitation/recrystallization from methylene chloride.
2-(Cyclopentylthio)cyclohexa-2,5-diene-1,4-dione
(2e)
Orange solid, yield 34%, 1H-NMR (CDCl3) δ: 6.832–6.714
(2H, m), 6.491 (1H, d, J=0.008 Hz), 3.461–3.445 (1H, m),
2.232–2.182 (2H, m), 1.860–1.714 (6H, m). LCMS m/z: 208
[M+].
2-(Heptylthio)cyclohexa-2,5-diene-1,4-dione (2f) Black
solid, yield 22%, 1H-NMR (CDCl3) δ: 6.844–6.720 (2H,
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m), 6.408 (1H, d, J=0.007 Hz), 2.800 (2H, t, J=0.024 Hz),
1.798–1.747 (2H, m), 1.499–1.472 (2H, m), 1.396–1.298 (6H,
m), 0.932 (3H, t, J=0.022 Hz). LCMS m/z: 238 [M+].
2-(Phenylthio)cyclohexa-2,5-diene-1,4-dione
(2g) Orange solid, yield 96%, 1H-NMR (CDCl3) δ: 7.523 (5H, bs),
6.854 (1H, d, J=0.033 Hz), 6.706 (1H, dd, J=0.033 Hz,
J=0.008 Hz), 5.918 (1H, d, J=0.008 Hz. LCMS m/z: 216 [M+].
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